Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Xenetic Biosciences, Inc.XBIO · Entity 8008 | Interim CEO and CFO | April 21, 2026 | April 23, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Xenetic Biosciences, Inc.
Report date April 21, 2026 · Filed April 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 100,000 |
Reported balance
After 2026-04-21 transaction · row 1
1 source rowRow 1 · 2026-04-21 · Grant · Acquired 100,000 · Balance 100,000 F1: This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 21, 2026 Filed Apr 23, 2026 21:00 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantCommon Stock | 100,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001683168-26-003163 · ownership.xml · nonDerivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Interim CEO and CFO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 100,000 F1 · kind: This represents a restricted stock grant ("RSG"). The shares represented by the RSG will vest and become exercisable as follows: 7,000 shares shall vest on the date of grant and one-third of the remaining (93,000) shares shall vest on each of the first, second and third anniversaries of April 21, 2026. Read SEC document |
| June 18, 2024 Filed Jun 21, 2024 21:00 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $3.99 | $0.00 |
DisclosureSEC source: 0001683168-24-004421 · ownership.xml · derivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Interim CEO and CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2034-06-18 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-fourth of the shares shall vest on the date of grant and one-fourth of the shares shall vest on each of the first, second and third anniversaries of June 18, 2024 ending on June 18, 2027. Read SEC document |
| December 11, 2023 Filed Dec 13, 2023 22:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 10,000 | $0.00 Strike: $3.88 | $0.00 |
DisclosureSEC source: 0001683168-23-008826 · ownership.xml · derivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,000 Underlying: Common Stock · 10,000 shares Expires 2033-12-11 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of December 11, 2023; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on March 11, 2025 and ending on December 11, 2026. Read SEC document |
| March 24, 2022 Filed Mar 28, 2022 21:14 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $1.12 | $0.00 |
DisclosureSEC source: 0001683168-22-002002 · ownership.xml · derivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2032-03-24 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 24, 2022; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 24, 2023 and ending on March 24, 2025. Read SEC document |
| March 18, 2021 Filed Mar 22, 2021 21:30 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 50,000 | $0.00 Strike: $2.60 | $0.00 |
DisclosureSEC source: 0001683168-21-001019 · ownership.xml · derivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2031-03-18 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: one-third of the shares shall vest on the first anniversary of March 18, 2021; the remaining two-thirds of the shares shall vest in eight equal quarterly installments commencing on June 18, 2022 and ending on March 18, 2024. Read SEC document |
| December 04, 2019 Filed Dec 6, 2019 23:42 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantStock Options · Derivative | 80,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001683168-19-003923 · ownership.xml · derivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 80,000 Underlying: Common Stock · 80,000 shares Expires 2029-12-04 F1 · derivative.exercise_date: The shares underlying the options will vest and become exercisable as follows: 26,666 shares shall vest on the first anniversary of December 4, 2019 ("Vesting Start Date"); 26,667 shares shall vest on the second anniversary of the Vesting Start Date; and 26,667 shares shall vest on the third anniversary of the Vesting Start Date. Read SEC document |
| April 03, 2017 Filed Apr 4, 2017 12:08 UTC | Xenetic Biosciences, Inc. XBIO · Entity 8008 | GrantEmployee Stock Option (Right to Buy) · Derivative | 175,000 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0001209191-17-024356 · doc4.xml · derivative · entry 1 PARSLOW JAMES F · CIK 0001285943 · Chief Financial Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,000 Underlying: Common Stock · 175,000 shares Expires 2027-04-03 F1 · derivative.exercise_date: The shares underlying the option will vest and become exercisable over three years, with one-third of the underlying shares vesting on each of April 3, 2018, April 3, 2019 and April 3, 2020, subject to the Reporting Person's continuous service with the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.